|  |  |
| --- | --- |
| Study ID | Adverse Drug Reactions |
| Griffiths et al. 2016a | * 0% HPPD * 0% prolonged psychosis * 34% transient elevated SBP (during drug treatment) * 13% transient elevated DBP (during drug treatment) * 15% nausea and/or vomiting (during drug treatment) * 21% physical discomfort (during drug treatment) * 32% psychological discomfort (during drug treatment) * 26% transient anxiety (during drug treatment) * 2% transient paranoid ideation (during drug treatment) * 2% HA (during drug treatment) * 18% HA (post-drug treatment)   N= 26 |
| Carhart-Harris et al. 2018 | * 5% uncommunicative (during drug treatment) * 75% transient anxiety (during drug treatment) * 40% HA (post-drug treatment) * 25% nausea (during drug treatment) * 15% paranoid ideation (during drug treatment)   n = 20 |
| Ross et al. 2016 | * 0% psychiatric ADR’s requiring pharmacological intervention (during drug treatment) * 0% hallucinogen drug-seeking behavior (post-drug treatment) 0% HPPD * 0% prolonged psychosis * 76% non-clinically significant HTN and/or tachycardia (during drug treatment) * 28% HA * 14% nausea * 17% anxiety (during drug treatment) * 7% transient paranoid ideation/thought disorder (during drug treatment)   n = 16 |
| Gasser et al. 2014 | * 0% panic * 0% SI * 13.6% affect lability (during drug treatment) * 4.5% anger (during drug treatment) * 22.7% anxiety (during drug treatment) * 4.5% bradyphrenia (during drug treatment) * 4.5% depersonalization (during drug treatment) * 9.1% derealization (during drug treatment) * 36.4% emotional distress (during drug treatment) * 4.5% euphoric mood (during drug treatment) * 40.9% feeling “abnormal” (during drug treatment) * 45.4% feeling cold (during drug treatment) * 4.5% feeling relaxed (during drug treatment) * 31.8% ataxia/gait disturbance (during drug treatment) * 4.5% hallucinations (during drug treatment) * 13.6% hyperhidrosis (during drug treatment) * 4.5% HTN (during drug treatment) * 72.7% illusion (during drug treatment) * 4.5% perseveration (during drug treatment) * 9.1% abnormal thought processes (during drug treatment) * 9.1% emotional distress (post-drug treatment) * 4.5% feeling abnormal (post-drug treatment) * 9.1% feeling cold (post-drug treatment) * 4.5% illusion (post-drug treatment)   n = 8 |
| Palhano-Fontes et al. 2019 | * 71% nausea (during drug treatment) * 57% vomiting (during drug treatment) * 50% anxiety (during drug treatment) * 43% HA (during drug treatment)   n = 14 |
| Grob et al. 2011 | * 0% HTN (during drug treatment) * 0% tachycardia (during drug treatment) * 0% psychological ADR’s   n = 12 |
| Zeifman et al. 2020 † | * 50% vomiting (during drug treatment)   n = 6   * SBP = 119 ± 23.02 mmHg * DBP = 76.4 ± 13.74 mmHg * HR = 72.2 ± 7.69 bpm   n = 5 |
| Davis et al. 2020 | * 79% sadness (during drug treatment) * 77% emotional or physical discomfort (during drug treatment) * 58% despair (during drug treatment) * 27% anxiety (during drug treatment) * 40% panic (during drug treatment) * 8% paranoid ideation (during drug treatment) * 2% SBP > 170 mmHg / DBP > 100 mmHg (during drug treatment) * 8% tachycardia >110 bpm (during drug treatment) * 33% HA   n = 48\* |
| Anderson et al. 2020 | * 5.6% of subjects experienced severe ADR’s, but all were determined to be unrelated to drug trial. * 66.6% HTN (during drug treatment) * 44.4% anxiety (during drug treatment) * 33.3% nausea (during drug treatment) * 27.8% HA (during drug treatment) * 22.2% Paranoia/IOR (during drug treatment) * 22.2% motor agitation (during drug treatment) * 22.2% ataxia (during drug treatment) * 11.1% tachycardia (during drug treatment) * 5.6% thought disorder (during drug treatment) * 5.6% urinary incontinence (during drug treatment) * 5.6% visual changes (during drug treatment) * 44.4% HA (post-drug treatment) * 11.1% fatigue (post-drug treatment) * 11.1% insomnia (post-drug treatment) * 5.6% anxiety exacerbation (post-drug treatment) * 5.6% posttraumatic stress flashback (post-drug treatment) * 5.6% nausea (post-drug treatment)   n = 18 |
| **Supplementary Table 3** *Reported adverse drug reactions (ADR)*. All ADR percentages shown are reported for only the experimental groups, not those receiving placebo. Any HTN ≥ 140/90 was considered HTN, further subclassification was not included here. \* sample size is 48 for this trial, as its 24 experimental subjects had two dosing sessions, ADR percentages are reported from across both sessions. † ADR data is reported in the initial publication using data from the subjects in this trial, which is presented here in this table (Osorio et al., 2015). Abbreviations: ADR= Adverse Drug Reactions; HTN = hypertension, SBP = systolic blood pressure; DBP = diastolic blood pressure; HPPD = hallucinogen persisting perception disorder; IOR = ideas of reference; HA = headache; SI = suicidal ideation. | |